The Effect of Vitamin K2 in Addition to Risedronate on the Patients with Postmenopausal Osteoporosis

Objective: To assess the effect of vitamin K2 in addition to risedronate on postmenopausal osteoporosis Method: We enrolled 21 postmenopausal osteoporosis women (age: 65.27.8 years). Ten subjects received risedronate (35 mg, weekly) and vitamin K2 (45 mg, daily) and eleven subjects only received risedronate. They all received calcium citrate 2,130 mg and vitamin D 600 IU daily. The duration of treatment was 7.71.4 months. Bone mineral density (BMD) of lumbar spine and both femurs, serum osteocalcin and urine deoxypyridinoline were examined at baseline and after treatment. Results: After treatment, BMD, serum osteocalcin and urine deoxypyridinoline were improved in each group but there was no statistical difference between the groups. Conclusion: There was no evidence of the benefit of vitamin K2 in addition to risedronate in bone metabolism on postmenopausal osteoporosis. (J Korean Acad Rehab Med 2006; 30: 491-495)